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Background: Circulating leptin:adiponectin ratio (L:A) is a potential surrogate marker for cardiometabolic diseases; however, the 
relationship of the L:A with the occurrence of metabolic syndrome (MetS) has not yet been fully explored in the general Japanese 
population.
Methods: We enrolled 678 Japanese subjects (208 men and 470 women, mean age: 58.8±14.4 [SD] yr; mean body mass index: 
23.6±3.3 kg/m
2) in this study, and determined their MetS status by using the National Cholesterol Education Program-Adult Treat-
ment Panel (NCEP-ATP) recommendations with minor modifications for the Japanese population. Biochemical markers such as 
leptin and adiponectin present in blood were measured. The statistical analyses performed were gender-based.
Results: The L:A in subjects with MetS was significantly higher than that in subjects without MetS, regardless of gender. The L:A 
also showed a significant and gradual increase corresponding to the increase in the number of components of MetS present in 
both the genders (trend P<0.01). The cut-off level of the L:A to detect MetS was 0.59 (sensitivity: 0.72, specificity: 0.70) in men and 
1.04 (sensitivity: 0.72, specificity: 0.69) in women.
Conclusions: These results suggest that the L:A can serve as a clinically useful marker for detecting MetS characteristics in the gen-
eral Japanese population. The clinical application of this laboratory index for detecting MetS should be assessed in future studies.
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INTRODUCTION
Metabolic syndrome (MetS), a cluster of metabolic disor-
ders such as obesity, hypertension, dyslipidemia, and hyper-
glyceridemia, increases the risk of developing atheroscle-
rotic diseases such as cardiovascular disease (CVD) [1-3]. 
Therefore, MetS is a major public-health concern world-
wide [4, 5].
Recently, 2 adipocytokines, leptin and adiponectin, have 
been recognized as key regulators of various metabolic dis-
orders, and the serum/plasma leptin:adiponectin ratio (L:A) 
has been reported to be a new surrogate marker for athero-
sclerosis in subjects with obesity and type 2 diabetes mellitus 
[6, 7]. The ratio of adiponectin and leptin has also been re-
ported to be associated with insulin resistance, which is con-
sidered to be one of the pathophysiological conditions un-
derlying MetS [8, 9]. However, for instance, diabetes melli-
tus, a component of MetS, is not always caused by insulin re-
sistance in Japanese people [10]. Furthermore, these earlier 
studies have not explored the association between L:A and 
MetS with regard to the determination of a potential cut-off 
level of L:A for detecting MetS and have not fully examined 
the L:A in the general community-dwelling population of 
Japan. Therefore, this study aimed to confirm whether the 
L:A can indicate MetS traits across a wide range of age in 
both men and women in the general Japanese population.
MATERIALS AND METHODS
A total of 678 non-smoking Japanese subjects (208 men 
and 470 women with a mean age of 58.8±14.4 yr [range: 21-Kotani K, et al.  •  L:A Ratio and Metabolic Syndrome
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88 yr]; a mean age of 60.2±15.2 yr [range: 24-88 yr] in men 
and 58.1±14.0 yr [range: 21-83 yr] in women) were selected 
from the people attending general health check-ups and 
community-based health education classes. The study was 
approved by the institutional ethics committees, and each 
subject gave informed consent. None of the subjects was 
taking any medication that is known to influence metabolic 
disorders, and they had not been previously diagnosed with 
CVD. The presence of 3 out of 5 of the following criteria 
was considered as a diagnosis of MetS according to the Na-
tional Cholesterol Education Program-Adult Treatment 
Panel (NCEP-ATP) III recommendations with a minor mo-
dification for the criteria for obesity [11, 12]: 1) obesity, ide-
ntified by a body mass index (BMI) ≥25.0 kg/m
2, as a sur-
rogate for increased waist circumference for Japanese peo-
ple [11, 12]; 2) elevated blood pressure (BP), identified by a 
systolic BP ≥130 mmHg and/or diastolic BP ≥85 mmHg; 
3) hypertriglyceridemia, identified by fasting serum triglyc-
eride values≥1.69 mmol/L; 4) decreased high-density lipo-
protein (HDL) cholesterolemia, identified by serum HDL 
cholesterol values <1.04 mmol/L in men and <1.29 mmol/
L in women, and 5) elevated glucose levels, identified by 
fasting plasma glucose values ≥6.1 mmol/L.
The BP was measured on the upper arm, with the subject 
in a seated position, by using a standard sphygmomanome-
ter. Blood glucose and triglyceride values were enzymati-
cally measured, and the HDL cholesterol values were mea-
sured using a homogeneous method. The serum samples of 
leptin and adiponectin were frozen until they were used for 
measurement (within 3 months). Leptin level was measured 
using an enzyme-immunoassay kit with intra- and inter-as-
say coefficients of variation of 5.6% and 6.7%, respectively 
(Cayman Chemical Company, Ann Arbor, MI, USA). Adi-
ponectin was measured using an enzyme-linked immuno-
sorbent assay kit with intra- and inter-assay coefficients of 
variation of 5.2% and 3.4%, respectively (Otsuka Pharma-
ceutical Co Ltd, Tokyo, Japan).
All values are expressed as the mean±standard deviation 
(SD) or median+interquartile range, unless otherwise speci-
fied. The between-group differences were analyzed by the t-
test or chi-square test. The within-group trends and differ-
ences were analyzed by one-way ANOVA with post-hoc 
tests for multiple comparisons. ANOVA was also perform-
ed with an adjustment for age. The variables associated with 
L:A were determined by a multiple linear regression analy-
sis after adjustment for age, systolic BP, triglyceride, HDL 
cholesterol and glucose levels (diastolic BP was not included 
in this analysis model because it had a close colinearity with 
the systolic BP). ROC curves were plotted to identify an op-
timal cut-off level of the L:A for detecting MetS [13]. The 
values of triglyceride, leptin, adiponectin, and L:A were cal-
culated after a log-transformation because of their skewed 
distribution. Differences were considered significant at P≤ 
0.05.
RESULTS
The characteristics of the subjects included in this study 
are shown in Table 1. Mean/median ages (women), levels of 
BMI, systolic BP (women), diastolic BP, triglyceride, glu-
cose, leptin, and L:A were significantly higher, whereas the 
mean/median levels of HDL cholesterol and adiponectin 
were significantly lower, in MetS subjects (men and women) 
than in non-MetS subjects.
The correlations between the L:A and the other cardio-
metabolic variables determined by the multivariate-adjust-
ed regression analysis are shown in Table 2. In men, the 
variables that were significantly and independently associ-
ated with the L:A were age (positively), BMI (inversely), 
triglyceride (inversely), and glucose (inversely). In women, 
the variables that were significantly and independently as-
sociated with the L:A were age (positively), BMI (inversely), 
triglyceride (inversely), and HDL cholesterol (positively).
A trend toward an increase in the L:A with an increase 
Table 1. Gender-based clinical characteristics of the subjects
Variable
Men Women
Non-MetS MetS Non-MetS MetS
Subject number (n) 158 50 384 86
Age (yr) 60.1±15.8 60.8±13.2 57.1±14.6 62.6±9.7
†
BMI (kg/m
2) 23.4±2.6 26.5±2.9
† 22.6±3.0 26.8±2.9
†
SBP (mmHg) 134.4±19.6 140.3±18.0 130.1±18.2 144.1±16.8
†
DBP (mmHg) 76.0±10.3 80.4±11.0
† 73.7±9.9 80.3±9.6
†
Triglyceride (mmol/L) 1.01 
(0.79-1.32)
1.89
 (1.59-2.65)
†
0.96 
(0.70-1.25)
1.85
 (1.37-2.41)
†
HDL-C (mmol/L) 1.41±0.37 1.17±0.29
† 1.68±0.36 1.25±0.28
†
Glucose (mmol/L) 5.46±0.98 6.57±2.56
† 5.29±1.11 5.91±1.16
†
Leptin (ng/mL) 2.37
 (1.11-4.14)
2.89
 (1.82-6.20)*
6.49
 (3.28-10.59)
12.80
 (7.36-21.56)
†
Adiponectin (μg/mL) 6.27
 (3.96-9.28)
3.96
 (2.91-6.09)
†
10.52
 (7.25-15.08)
7.64
 (5.11-12.18)
†
Leptin:adiponectin ratio 0.34
 (0.17-0.77)
0.86
 (0.46-1.35)
†
0.61
 (0.28-1.24)
1.47
 (0.78-3.11)
†
*P≤0.05; 
†P≤0.01: statistically significant (gender-based comparison between 
subjects with and without MetS). The triglyceride, leptin, adiponectin levels and the 
leptin:adiponectin ratio were log-transformed for the analyses because of their 
skewed distribution.
Data are presented as the mean±SD or medians (interquartile range).
Abbreviations: MetS, metabolic syndrome; BMI, body mass index; SBP, systolic blood 
pressure; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol.164     www.kjlm.org
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in the number of components of MetS was observed, as 
shown in Table 3. Only 6 (2 men and 4 women) of the sub-
jects presented with all 5 components of the MetS; there-
fore, the group of subjects presenting with all 5 components 
of MetS was combined with the group presenting with 4 
components to form a group presenting with ≥4 compo-
nents of MetS. On the basis of the number of components 
of MetS, the L:A levels were found to have a significantly 
and gradually increasing trend in all subjects, regardless of 
gender.
Fig. 1 shows the ROC curves for the L:A. The area under 
the ROC curve was 0.712 (95% confidence interval: 0.632-
0.791, P<0.0001) in men and 0.755 (95% confidence inter-
val: 0.700-0.809, P<0.0001) in women. On the basis of the 
plotted ROC curves, the cut-off level of L:A for detecting 
MetS was determined to be 0.59 (sensitivity: 0.72, specific-
ity: 0.70, positive likelihood ratio: 2.4, negative likelihood 
ratio: 2.5) in men and 1.04 (sensitivity: 0.72, specificity: 0.69, 
positive likelihood ratio: 2.3, negative likelihood ratio: 2.5) 
in women.
DISCUSSION
In the subjects of the present study, the L:A levels were 
significantly higher in MetS subjects than in non-MetS sub-
Table 2. Gender-based multivariate-adjusted correlations of the leptin: adi-
ponectin ratio with the other variables
Variable Men Women
Age (yr) 0.252 (<0.0001)
† 0.202 (<0.0001)
†
BMI (kg/m
2) - 0.258 (<0.0001)
† - 0.152 (0.002)
†
SBP (mmHg) 0.074 (0.272) - 0.014 (0.781)
Triglyceride (mmol/L) - 0.157 (0.019)* - 0.136 (0.007)
†
HDL-C (mmol/L) 0.062 (0.344) 0.245 (< 0.0001)
†
Glucose (mmol/L) - 0.129 (0.039)* - 0.0004 (0.928)
*P≤0.05; 
†P≤0.01: statistically significant (by a multiple linear regression analysis 
adjusted for all of the listed variables by gender).  The triglyceride and the leptin: adi-
ponectin ratio were log-transformed for the analyses because of their skewed distri-
bution.
Data are presented as β-correlation coefficients (P values).
Abbreviations: BMI, body mass index; SBP, systolic blood pressure; HDL-C, high-densi-
ty lipoprotein cholesterol.
Table 3. The levels of leptin:adiponectin ratio according to the number of 
components of metabolic syndrome
Number 0 1 2 3 ≥ 4
Men
(N=208)
† (27) (72) (59) (41) (9)
0.22 
(0.09−0.55)
0.40 
(0.20−0.79)
0.35 
(0.16−0.85)
0.72 
(0.40−1.23)
a
1.34 
(0.77−3.54)
b
Women
(N=470)
† (138) (153) (93) (66) (20)
0.50 
(0.25−0.84)
0.58 
(0.24−1.21)
1.11 
(0.43−2.02)
c
1.41 
(0.80−2.81)
d
2.12 
(0.71−5.06)
e
Number; number of components of metabolic syndrome.
P≤0.05: statistically significant. The values of leptin: adiponectin ratio were calcu-
lated after a log-transformation because of the skewed distribution.
A trend test within the group (ANOVA): *P≤0.01; 
†P≤0.01; these P values were not 
changed after adjusting for age.
The difference between the number-based groups (multiple comparison test): Men, 
aP≤0.01 vs. number-0, 0.039 vs. number-2; 
b≤0.01 vs. number-0, 0.024 vs. num-
ber-1, 0.016 vs. number-2. Women, 
cP≤0.01 vs. number-0, ≤0.01 vs. number-1; 
d≤0.01 vs. number-0, ≤0.01 vs. number-1, 0.030 vs. number-2; 
e≤0.01 vs. num-
ber-0, ≤0.01 vs. number-1, 0.044 vs. number-2.
Data are presented as medians (interquartile range).
Fig. 1. ROC curve for the leptin:adiponectin ratio (L:A) for gender-based detection of metabolic syndrome. (A) Men, (B) women. The reference line represents the 
ROC curve for a statistical test with no discriminatory ability. The area under the ROC curve was 0.712 (P<0.0001) and the L:A cut-off level was 0.59 (sensitivity, 
0.72; specificity, 0.70) in men, and the area under the ROC curve was 0.755 (P<0.0001) and the L:A cut-off level was 1.04 (sensitivity, 0.72; specificity, 0.69) in 
women. P≤0.05: statistically significant.
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jects, regardless of gender. The L:A was shown to be signifi-
cantly and positively associated with the number of compo-
nents of MetS present in both genders. The L:A was also 
significantly and independently associated with each MetS-
component variable such as the BMI, triglyceride and glu-
cose levels (in men), and HDL cholesterol levels (in women).
Leptin and adiponectin are individually known to be in-
volved in the pathogenesis of obesity and MetS [6, 14, 15]. 
Under such an obesity-related condition, the leptin levels 
are higher and adiponectin levels are lower, and thus, the 
L:A can be relatively high [6, 7]. This fact seems to explain 
the results obtained in the present study. On the basis of 
these results, the L:A can be considered to be a plausible in-
dex for detecting the presence or the multiple components 
of MetS. In addition, although the reasons for the between-
gender differences in the association of the L:A with glu-
cose/lipid variables of MetS components remain unclear, it 
may be partially due to gender-based differences in glucose 
and lipid (i.e., HDL cholesterol) metabolism, requiring fur-
ther research [16, 17].
Simultaneous occurrence of multiple components of 
MetS reportedly contribute to the development of CVD [1, 
2]. Leptin and adiponectin can be more relevant to athero-
sclerosis in subjects with obesity and diabetes mellitus than 
conventional atherosclerotic factors such as BP and lipid 
levels [7, 14, 15]. In this study, we proposed a gender-based 
cut-off level of L:A for the detection of MetS in the general 
Japanese population; thus, this may be valuable in future 
studies. These proposed values had a moderate degree of ac-
curacy for the area under the ROC curves, as well as showed 
a twofold higher L:A cut-off level for MetS in women than 
in men. Whether an increase in the L:A or the L:A cut-off 
level can predict the development of CVD in MetS is an im-
portant issue that will need to be examined in more studies.
A possible limitation of this study is that it was designed 
to be cross-sectional. In the present study, although we de-
termined the variables associated with L:A, the cross-sec-
tional design did not clearly elucidate the cause-and-effect 
relationship between these variables. The prevalence of 
MetS in women of the present study appeared to be high in 
a comparison to a prior study [18]. Because these results 
might be partially affected by the study settings and meth-
odologies (e.g., the recruitment of subjects, and diagnostic 
criteria for MetS), the generalizability of the results must be 
interpreted carefully. Unfortunately, we did not measure the 
waist circumference, fat distribution (e.g., by computed to-
mography) and nutritional status, which might also influ-
ence the L:A. More studies with a prospective design and 
including various other measurements are needed to con-
firm our theory.
In summary, our results suggest that the L:A can serve as 
a clinically useful marker for MetS traits in the general Japa-
nese population. The clinical significance of the L:A as an 
easily determinable value for the management of MetS and 
the atherosclerotic disease associated with MetS in this pop-
ulation warrants further study.
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